American Cannabis Partners M&A Strategy Key Component of Growth Plan

 

• Report notes that global mergers and acquisition will continue into new year
• ACP performs months of due diligence before acquiring any properties
• Company exploring land acquisition, project development strategies for expanding operations to two more states this year

Mergers and acquisitions (M&A) appear to be a key component for companies looking to grow, with a recent 2022 Global M&A Trends Report indicating that M&A will continue in the new year (https://nnw.fm/8VYkF). Contending for first place in the U.S. cannabis industry, American Cannabis Partners (“ACP”) relies on proven strategies such as mergers and acquisitions to strengthen its position in a competitive market. 

“Through an analysis of M&A deal activity across seven to thirteen sectors, with breakdown for each region, the [Global M&A Trends Report] concludes that we should expect further, unprecedented global growth in 2022,” the article stated. “While the pandemic has continued to impact the wider market and M&A deal terms over the course of 2021, its impact has diminished from the preceding year. Across nearly all regions, practitioners agreed that due diligence was of paramount importance to doing deals in 2021.”

Due diligence is a top priority for ACP; on its website, the company notes that it “performs months of due diligence before acquiring any properties. Our sights are set on listings in cannabis friendly states, cannabis population demand, agricultural zoning, available licenses, and market value. Land and equipment are purchased in full to keep American Cannabis Partners debt free, tangible, and liquid available. After acquisitions, cost-effective measures are taken to update and appraise properties to increase market value” (https://nnw.fm/cPrXu). 

ACP CEO Stephen Jordan echoed this philosophy when he noted that the company focuses on “‘assets, assets, assets — and then build(s) the operations out,’ a rare approach in the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under” (https://nnw.fm/MzhFH).

The company recognizes that state and federal regulations can fluctuate wildly, but as a multistate operator, ACP can pivot within the fluctuations of each state’s laws. This focus on maintaining the ability to liquidate, move and survive is a fundamental strategy that allows American Cannabis Partners to protect its shareholders.

ACP is in the process of exploring land acquisition and project development strategies for expanding operations to additional states this year. With a total of 12 cannabis licenses, including 20,000 square feet of cultivation licenses in California and 540,000 square feet of cultivation licenses along with one retail license in Michigan, ACP is committed to becoming a leader in the U.S. cannabis industry.

For more information, visit the company’s website at www.ACPFarms.com.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://nnw.fm/ACP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

 

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs
• Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility 
• The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for cannabis, most recently at the annual Emerald Conference where he addressed artificial intelligence improvements
• U.S. health agencies have reported a four-fold increase in mental health concerns during the ongoing COVID-19 pandemic, demonstrating the rising need for responsive treatments

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is showcasing the scientific talent driving its efforts to improve the production processes throughout the cannabis value chain for more effective use of the plant’s chemical properties, as demonstrated by DELIC Labs’ President and Chief Science Officer Dr. Markus Roggen’s presentation on Delic’s craft cannabis extraction research Feb. 28 at the annual Emerald Conference (https://nnw.fm/RKJjR). 

Roggen’s presentation on “Artificial Intelligence for Craft Cannabis Products” highlights the lab’s experimental studies on the extraction behavior of solvents in developing a machine learning algorithm that can optimize extraction processes autonomously (https://nnw.fm/4vcRG), building on the company’s long-range efforts to increase control over production processes that were addressed by Roggen at CannMed a few years ago in a speech subsequently shared on YouTube (https://nnw.fm/SJYBv).

DELIC Labs is a federally authorized psilocybin and cannabis research laboratory that dedicates its efforts to improve extraction, analytical testing, and chemical processes. The laboratory’s R&D solutions for product lines and new intellectual property (“IP”) serve as the engine for the company’s overall ecosystem. 

In addition to the scientific backbone of the ecosystem, Delic’s health operations aim to help people live better lives through the largest ketamine clinic chain in the United States, Ketamine Wellness Centers (“KWC”) operating a dozen locations strategically located in secondary cities to improve accessibility and reach and serve the greatest number of patients.

The clinics have overseen thousands of mental health treatments to date, and the company plans to open 14 more clinics by mid-2023, according to a January corporate update (https://nnw.fm/4oBtc). 

The third component of Delic’s ecosystem is the company’s educational and promotional efforts through a variety of media outlets, including its Reality Sandwich digital magazine, a public education platform that provides psychedelic guides and news, streaming episodes on Delic Radio, and the company’s psychedelic wellness summit — Meet Delic — which drew more than 2,000 in-person attendees when it debuted in Las Vegas last fall (https://nnw.fm/FO2k4). 

Delic’s scalable approach to making psychedelic-based treatments a regular part of emotional health management is aimed at “giving people their best selves back.” 

During the advent of the COVID-19 pandemic, mental health concerns have only intensified. As noted in a Desert Sun report, 4 in 10 U.S. adults have reported symptoms of anxiety or depression during the pandemic — a four-fold increase from 2019.

“While vaccines afford significant immunity from the worst physical effects of the virus, the trauma of widespread death, illness and isolation is considerably harder to inoculate against,” the report states (https://nnw.fm/7uPbF). 

“At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S.,” Delic Co-founder and CEO Matt Stang stated during the corporate update. “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis. We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. … Delic is well-positioned for growth and profitability in 2022 and beyond.”

For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://nnw.fm/DELCF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Agreement Injects Capital, Expands International Distribution Opportunities

 

• The company recently announced a strategic private placement executed with agribusiness Nurture Healthy Foods to bring in just over $5 million in capital at $0.75 for M&A and general operations
• Plant-based consumer products brand builder Eat Well Investment Group Inc. is a growing investment company operating in North American markets
• Eat Well’s agreement with Nurture Healthy Foods includes an economic interest in Eat Well’s majority ownership of Amara Organic Foods, a growing manufacturer of plant-based baby foods
• The company’s products are also gaining increased distribution through companies such as Walmart, Whole Foods, Sprouts Farmer’s Market, Loblaws and HEB Grocery Company (H-E-B)

Vertically integrated plant-based foods investment company Eat Well Investment Group (CSE: EWG) (OTC: EWGFF), is securing new capital at $0.75 per Unit for M&A and general working activity, according to a recent announcement that notes not only a new round of private placement funding but also the sale of an interest in its portfolio company PataFoods, Inc. 

“This morning we shared with the markets that Nurture Healthy Food LLP has come in for a strategic private placement with us, approximately $5 million,” Eat Well CEO and Director Marc Aneed told Shoran Devi in a Feb. 15 interview with The Power Play (https://nnw.fm/XPpJG).

“The team at Nurture are like-minded to us. They are ESG (Environmental, Social and Governance factor)-driven, they are business builders and they are all about our mission, which is to feed families globally,” Aneed added. “This gives us strategic growth internationally through commercial, retail and distribution opportunities, as well as looking at deeper parts of their agribusiness portfolio and their plant-based solutions that we can bring to the world.”

Eat Well Investment Group has customers in over 35 countries already, but the agreement with Nurture Healthy Food will help the company’s customer and distribution relationships “exponentially move into the future,” Aneed said. 

The company generated nearly $60 million (Canadian) in revenue last year during a breakout year when it acquired plant-based ingredients processor Belle Pulses and plant-based food creator Sapientia and added an OTC listing in the United States to its Canadian Stock Exchange profile. Eat Well expects to report top-line earnings between $90 million and $110 million by the end of this year.  

“We couldn’t be more excited to find ways to blueprint our distribution growth throughout South America, Latin America with their strength that they (Nurture Healthy Food) have today in retail,” Aneed said. 

Eat Well acquired 51 percent ownership of Pata Foods (dba baby food brand Amara Organic Foods) last year with an option to obtain up to 80 percent if it wishes. Amara reported 533 percent revenue growth during 2021 and was named Amazon’s top new release (https://nnw.fm/LA7Tf).

The economic interest in Amara that Eat Well sold to Nurture entitles Nurture to receive 8 percent of the net proceeds or other property received by Eat Well if a liquidation event occurs in regard to Amara, such as a merger or the sale of any portion of the company’s overall equity interest in Amara, as well as 8 percent of any dividend declared and paid by Amara to Eat Well (https://nnw.fm/LpfKB).

Eat Well’s growth strategy includes recent announcements that Amara will be distributed through over 400 Walmart stores in Canada and online through Walmart’s e-commerce platform, as well as through Loblaws’ Canadian stores nationwide and through 200 of food retailer HEB Grocery Company (H-E-B) stores in the United States.

For more information, visit the company’s website at www.EatWellGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://nnw.fm/EWGFF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

GreenBox POS (NASDAQ: GBOX) and Cross River Join Forces to Create First Banking-as-a-Service Initiative

 

• GreenBox will build the first banking-as-a-service initiative, catapulting the company into the same playing field as other major FinTech-driven brands
• CEO Fredi Nisan said the initiative will be a game changer for the company, expanding its capabilities and potential customer base, while also serving as a significant driver of revenue growth 
• The partnership will provide additional services to existing clients on a single, seamless platform with a full suite of services that position the two companies to be a vertically-integrated full solution service

GreenBox POS (NASDAQ: GBOX), an emerging financial technology (FinTech) company that leverages proprietary security and token technology to build customized payment solutions for businesses, has announced entering a licensed partnership with Cross River. Cross River is a technology-driven infrastructure provider offering embedded financial solutions. The licensed partnership brings GreenBox closer to building compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving, and dynamic market worldwide (https://nnw.fm/2tDiM).

Cross River is known for merging innovative state-of-the-art technology capabilities with the expertise of traditional banking, which is currently powering multiple leading FinTech companies across the United States. Through the partnership with Cross River, GreenBox will bring to realization its first banking-as-a-service initiative. This strategic move by GreenBox will catapult the company into the same playing field with other major FinTech-driven brands.

“This was an important and necessary first step towards the launch of banking as a service which we believe will be a game-changer for GreenBox as it will radically expand our capabilities and the vast universe of potential customers, with a customer-inspired, technology-driven and combined offering,” GreenBox CEO Fredi Nisan said, talking about the partnership. “Not only will we eventually be able to offer all our existing merchant clients cutting edge banking services, but we can also open these solutions to strategic partnership and enterprises seeking white label solutions. We expect this to be a significant driver of revenue growth.” 

The infrastructure and payment rails provided by Cross River will enable GreenBox to open accounts (custodial, reserve, and operating accounts) for customers, which can be managed with a full suite of tools, all of them powered by Cross River. Resulting advantages include the potential creation of new channels to add customers, leading to great levels of revenue growth. Combining GreenBox technology with Cross River’s infrastructure will provide additional services to existing clients on a single, seamless platform with a full suite of services.

“Joining forces with GreenBox highlights Cross River’s ability to do what we do best: empower innovative and responsible fintech companies to provide their customers with access to transparent, secure, and reliable financial solutions,” Cross River’s EVP and Head of FinTech Banking, Adam Goller, said. “We’re elated to be leading the way with GreenBox in advancing the digital finance landscape into a hassle-free, all-inclusive, and technology-centered experience for businesses and consumers alike.”

Nisan also underlined that Cross River was the perfect partner to launch this ambitious initiative with, given their expertise in banking technology. “This represents yet another example of us executing against our master plan for expansion, with a trusted, tech-forward bank whose mission is aligned with our own. Together, we will be a disruptive force in the FinTech landscape, enabling the sustainable, long-term value our shareholders expect.”

The initial phase of the partnership will serve as a foundation for banking-as-a-service solution. This offers customers a superior experience through a centralized hub under a user-friendly platform. The overall offering will roll out in multiple phases, delivering exceptional advantages like security, efficiency, and rapid transaction settlement across a wide range of capabilities. 

For more information, visit the company’s website at www.GreenBoxPOS.com. 

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://nnw.fm/GBOX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

 

• Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005
• This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds
• Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea
• The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term

Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a psychoactive experience, has been gaining popularity recently. It has been lauded as a viable method of treating specific mental health conditions such as depression, anxiety, and attention-deficit/hyperactivity disorder (“ADHD”). However, more research is needed to confirm its safety and efficacy.

One of the main issues that have been highlighted is the substantial medical risk involved with microdosing. Psilocybin, for instance, has shown a binding affinity to the 5-HT2B receptor, which is, in turn, linked to heart valve tissue fibrosis. As such, its consumption, over a long period, could present a patient with cardiovascular health concerns, a legitimate risk that ought to be considered (https://nnw.fm/9TM3m). 

In a significant move that remedies the situation, Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced its latest drug discovery and its first of many for the new year, MYCO-005. Essentially a novel molecule in its family of psilocin analogs, MYCO-005 has proven to have potentially heart-safe microdose enabling properties while addressing the shortcomings and limitations associated with the first-generation compounds.

“We are very excited about our MYCO-005 family of molecules,” noted Josh Bartch, the Chief Executive Officer (“CEO”) of Mydecine.

“Not only have we made improvements to this second generation of compounds to specifically address concerns for medical use, like onset time and shelf stability, but now we believe we have also identified a microdosing compound that is safer than what’s currently available on the market,” he added.

Mydecine’s patent-pending dermal route to administration offers more control over the drug while also potentially eliminating undesirable properties including, but not limited to, nausea. This is achieved by bypassing the digestive system. 

Going forward, the company seeks to explore this new feature and study its patent-pending skin permeation technology to produce a low-dosed, time-released patch that does not result in hallucinations for the patient.

“This is one of the many exciting drug discoveries we look forward to sharing in the near term,” noted Mr. Bartch.

This significant milestone for Mydecine proves its commitment to transforming the treatment of mental health and addiction disorders, particularly with psychedelics. It also shows its commitment to research and creating value for its shareholders.

For more information, visit the company’s website at www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://nnw.fm/MYCOF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation

 

• Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
• The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
• Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
• The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation

Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”).

“We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success,” Lexaria CEO Chris Bunka wrote in a January 27 annual update to its stakeholders (https://nnw.fm/gQHZ6). 

The company’s multifaceted operational approach leverages its versatile and disruptive DehydraTECH(TM) technology, which is currently protected by a total of 23 granted patents worldwide. Designed specifically for delivering fat-soluble drugs and active pharmaceutical ingredients, DehydraTECH pairs the active ingredients with a fatty acid oil, such as high oleic sunflower oil. It then applies the resultant compound to food or carrier particles such as sorbitol or gum Arabic before a dehydration synthesis procedure is performed. The final step entails rendering the product as powder or liquid (https://nnw.fm/qzBn3). 

“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website reads. And multiple studies have supported this statement.

Most recently, Lexaria announced positive results from an animal study, PDE5-A21-1, investigating DehydraTECH processing of PDE5 inhibitor sildenafil for potential application in the management of erectile dysfunction. Conducted at a US-based, third-party independent laboratory, the study involved 20 male Sprague-Dawley rats, half of which were treated with one dose of the DehydraTECH-sildenafil, with the rest receiving generic concentration-matched, control-sildenafil formulation.

The PDE5-A21-1 study showed that DehydraTECH technology delivered 74% more sildenafil into the bloodstream on average than the control just four minutes after dosing. After another three minutes, the DehydraTECH-sildenafil formulation reached an average blood level higher than the control formulation achieved at any point during the study. Further, the DehydraTECH-sildenafil reached a maximum concentration in the bloodstream (“Cmax”) that was approximately 70% higher and at a 25% faster rate than generic sildenafil control formulation. 

With the common complaint among many sildenafil users being that it is slow to act, the findings of the PDE5-A21-1 study could usher a new dispensation as regards the development of better and faster-acting sildenafil oral formulations. The results supported further investigation involving a larger number of animals.

Overall, Lexaria aims to leverage positive results from such studies to journey step by step toward removing risks associated with commercialization and regulation. Eventually, the company says, with enough positive data, the formula will tilt in its direction. 

“Our R&D focus for 2021 was to investigate DehydraTECH-CBD for possible hypertension and heart disease applications; to further our knowledge of DehydraTECH-nicotine as a replacement for damaging and deadly lung-based absorption methods; and to learn whether DehydraTECH would be compatible with antiviral drugs. We were successful in each of these primary areas of investigation,” Bunka wrote.

Looking ahead to 2022, Lexaria plans to launch three major studies between March and April: the human sublingual/buccal tissue study (oral nicotine), the animal seizure study (“CBD”), and its most ambitious study yet, the 6-week human hypertension study (“CBD”). The goal of these three studies is to generate sufficient data to support either regulated IND-type applications or influence corporate partnerships. At the same time, Lexaria will also be conducting several smaller studies throughout the year and will update shareholders when appropriate. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.